13F Holdings
中文EN

IKT Inhibikase Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1750149 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-45.1%
TTM EPS YoY-185.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-52.9%
ROA-49.2%
ROIC (approx.)-68.9%
Asset turnover—

Leverage & solvency

Liabilities / assets6.4%
Debt / equity0.00x
Current ratio15.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$0$260,501$123,440$3.10M
R&D expense$29.79M$17.21M$13.62M$12.03M$11.36M
SG&A expense$23.56M$11.38M$6.73M$6.22M$6.51M
Operating income-$51.97M-$28.59M-$20.09M-$18.13M-$14.77M
Interest expense————$19,923
Pretax income-$48,259-$27,520———
Income tax$0$0———
Net income-$48.26M-$27.52M-$19.03M-$18.05M-$14.79M
EBITDA-$51.91M-$28.56M-$19.91M-$18.12M-$14.77M
EPS (basic)-0.49-1.16-3.16-4.28-0.81
EPS (diluted)-0.49-1.16-3.16-4.28-0.81
Weighted avg. shares (diluted)98.31M23.71M6.03M4.22M18.21M
Banking
Net interest income$3.72M$1.07M$1.06M$74,453-$19,923
Balance sheet
Cash & equivalents$139.22M$56.49M$9.17M$7.19M$40.75M
Short-term investments$39.54M$41.05M$4.09M$15.86M$0
Current assets$180.11M$98.45M$14.21M$24.37M$42.47M
PP&E, net$0$47,100$73,372$236,532$0
Total assets$181.20M$98.60M$14.51M$24.94M$42.47M
Current liabilities$8.30M$3.73M$3.44M$3.70M$4.05M
Short-term debt$0$110,517$150,095$145,836$0
Long-term debt——$381,784—$248,911
Total debt——$531,879—$248,911
Total liabilities$8.30M$3.73M$3.53M$3.90M$4.05M
Shareholders' equity$172.90M$94.87M$10.98M$21.04M$38.42M
Net debt——-$8.63M—-$40.50M
Shares outstanding131.69M69.36M6.19M4.22M25.16M
Cash flow statement
Operating cash flow-$27.79M-$19.15M-$18.09M-$17.35M-$14.30M
Capital expenditure$13,399$0$14,238$243,255$0
Free cash flow-$27.80M-$19.15M-$18.10M-$17.59M-$14.30M
Investing cash flow$2.05M-$37.00M$11.66M-$16.01M$0
Financing cash flow$108.46M$103.48M$8.41M-$204,769$41.09M
Depreciation & amortization$60,499$26,272$177,398$6,723$0
Stock-based compensation$15.31M$8.14M$500,148$458,147$1.53M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.